LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Andernach, 11.07.2025 – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company today announced the successful closing of its acquisition of Renaissance Lakewood, LLC (“Renaissance”), a US-based contract development and manufacturing organization (CDMO) specializing in nasal sprays and sterile dosage forms. The transaction, previously announced on October 13, 2025, has now been completed following regulatory approvals, terms of the transaction were not disclosed

With this acquisition, Renaissance’s facilities and team of approximately 500 employees become part of the global LTS network, joining existing sites in Germany, the US, and Israel. This strategic move significantly broadens LTS’s capabilities in the CDMO sector, enabling the company to offer an expanded range of drug delivery solutions and further strengthening its position as a global leader in innovative drug delivery.

Renaissance will be integrated into LTS as a new division named LTS Nasal & Sterile Drug Products. Serge Maltais, previously President and CEO of Renaissance, will lead the division as President and General Manager.

Bas van Buijtenen, LTS CEO, commented: “With the closing of this transaction, we are proud to welcome Renaissance Lakewood to the LTS family. By combining strengths, we can create more impact – for our partners, our patients, and the broader healthcare community. Together, our expanded capabilities and shared commitment to innovation will enable us to set new standards in drug delivery and CDMO services worldwide. We are excited to welcome Serge and his talented team to our organization”.

About LTS Lohmann Therapie-Systeme AG
We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches (“MAP”) for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China. Learn more about LTS www.ltslohmann.com.

For further information, please contact:
LTS Lohmann Therapie-Systeme AG
Dr Iris Schnitzler: iris.schnitzler@ltslohmann.com